Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.
about
Current and future directions for treating hepatitis B virus infectionHepatitis B and liver transplantation: molecular and clinical features that influence recurrence and outcomeManagement of chronic hepatitis B infection: current treatment guidelines, challenges, and new developmentsAsian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.Coexistence of HBsAg and HBsAb in a difficult-to-treat chronic hepatitis B: loss of HBsAg with entecavir plus tenofovir combinationDetection of Hepatitis B Virus M204I Mutation by Quantum Dot-Labeled DNA Probe.Early experiences from one of the first treatment programs for chronic hepatitis B in sub-Saharan AfricaChronic hepatitis B in 2014: great therapeutic progress, large diagnostic deficit.Virologic and serologic outcomes of mono versus dual HBV therapy and characterization of HIV/HBV coinfection in a US cohort.AASLD guidelines for treatment of chronic hepatitis B.Clinical Relevance of Minimal Residual Viremia during Long-Term Therapy with Nucleos(t)ide Analogues in Patients with Chronic Hepatitis B.Antiviral therapies and prospects for a cure of chronic hepatitis B.Present and future therapies of hepatitis B: From discovery to cureComparison of tenofovir plus lamivudine versus tenofovir monotherapy in patients with lamivudine-resistant chronic hepatitis BEfficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load.Optimizing antiviral agents for hepatitis B management in malignant lymphomas.Tenofovir is superior to entecavir for achieving complete viral suppression in HBeAg-positive chronic hepatitis B patients with high HBV DNA.UGT1A1*28 relationship with abnormal total bilirubin levels in chronic hepatitis C patients: Outcomes from a case-control study.Long-term therapy for chronic hepatitis B: hepatitis B virus DNA suppression leading to cirrhosis reversal.Current developments in nucleoside/nucleotide analogues for hepatitis B.Chronic hepatitis B virus infection: epidemiology, prevention, and treatment in China.Optimal therapy of chronic hepatitis B: how do I treat HBeAg-positive patients?Hepatitis B: 50 years after the discovery of Australia antigen.An evaluation of entecavir for the treatment of chronic hepatitis B infection in adults.Immune balance in Hepatitis B Infection: Present and Future Therapies.Review article: long-term safety of nucleoside and nucleotide analogues in HBV-monoinfected patients.Cost-Effectiveness Comparison Between the Response-Guided Therapies and Monotherapies of Nucleos(t)ide Analogues for Chronic Hepatitis B Patients in China.Week 4 viral load predicts long-term suppression of hepatitis B virus DNA during antiviral therapy: improving hepatitis B treatment in the real world.Induction of IFN-λ3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection.Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial.Randomized, controlled trial of entecavir versus placebo in children with hepatitis B envelope antigen-positive chronic hepatitis B.Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial.Randomized, three-arm study to optimize lamivudine efficacy in hepatitis B e antigen-positive chronic hepatitis B patients.Low-dose short-term hepatitis B immunoglobulin with high genetic barrier antivirals: the ideal post-transplant hepatitis B virus prophylaxis?Changes of HBsAg and HBV DNA levels in Chinese chronic hepatitis B patients after 5 years of entecavir treatment.Renal safety of tenofovir and/or entecavir in patients with chronic HBV monoinfection.Who will have the best response to entecavir?Combination nucleos(t)ide analogue as initial treatment for chronic hepatitis B: have we put this to rest?Negative HBcAg in immunohistochemistry assay of liver biopsy is a predictive factor for the treatment of patients with nucleos(t)ide analogue therapy.Nucleic acid polymer REP 2139 and nucleos(t)ide analogues act synergistically against chronic hepadnaviral infection in vivo.
P2860
Q26851240-AD7E84F5-8573-4E6B-8803-96CA236B0D99Q26859121-7AC8BF08-C4CF-490B-A9EA-463655A2B05FQ27008984-AD469126-4085-49DE-A00C-30EBB74B4ED4Q30391932-B2ADDD49-0C39-42F1-B262-25FF1B10FE28Q33651263-877324C9-75F7-43C6-8C10-35B0B980BF67Q33769738-F5771A17-011A-4E5F-AE9C-405E96453293Q33815159-181E5086-B420-448D-A7BC-60A767781130Q34137291-73FA4FE1-443D-4EE1-9E05-AA9CEB76A676Q34213161-90DDE01D-BB55-42AB-8008-AD8B5935FFE9Q34501660-01F9C36F-8F51-4C7B-9A79-2A7D31AB42B7Q34797281-BE0A414B-EE79-40FD-A9AF-4A2519679C0CQ35245231-F9E87EF5-F728-4EDD-A7AD-05DD279E6786Q36378278-7A211764-288C-45DC-B4DC-DCEA3205394DQ36779207-9047E9F6-3F86-4B59-A8BA-FACED48E7898Q37346823-B2CA7F89-8554-4011-A556-48253278E58EQ37666948-929DBC5F-C13D-4BA7-8440-A98C293C560BQ37722853-B5152034-1FDE-42ED-8F0D-6B96D52627E2Q37725310-4BCECEF9-6280-45CF-9B8A-F92C2E8B9B0EQ38097858-2702DA2F-16F9-4F7D-863D-6CF0AB62CCEDQ38208628-419E7F8C-DA79-44D1-A6D8-380F2F9024E8Q38210344-22EDE413-BE60-42DE-B92E-5403E7E0DAD0Q38295850-C78908C2-E97D-4B51-A595-CD2A13DCBEC4Q38568256-322732DF-C9D1-4498-987F-C9A8B705858EQ38648688-CD66C36C-7EBB-41B4-9C33-543A048D9895Q38733622-079A8BA1-325A-4B11-8E4A-2D5FD1A6F540Q38839020-4321186B-AEB8-4036-8F7E-B62C7F756E75Q39121074-D3BE94A5-606C-435E-9A5C-2813645B4A68Q39443390-8AFFBF26-A176-417E-AD12-D1853BAE1BC3Q40476048-D3F37276-F174-40AC-BB9B-1DE30B523587Q41175515-852C6682-DAB1-4FA3-BAE6-B7654D759557Q41533462-AB616FF5-A658-404C-9E3A-BA0036AF98E2Q41538789-FBFC3245-D55F-4073-93EB-93305E1DB750Q41685901-EC288182-5637-41DC-B847-E13EA56D1C67Q42164812-E471EBAC-A7BE-4968-B40D-8EDCF09C4573Q42249938-850BF32B-2CA4-4C4C-92AA-57F90A1E5C34Q42370608-594D7459-12CC-47CD-90CB-172BCCF398AFQ44288703-1AEB329F-605E-4796-B89A-72224AFB8862Q45775239-D8C64875-807B-40B1-9D5B-A948C905EE0AQ46191895-F6729CD0-FC08-4522-9032-978C7ECF865DQ47564306-2BE3037C-3B9C-4FA9-A115-4CF813DAA442
P2860
Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos
@nl
Efficacy of entecavir with or ...... ents with chronic hepatitis B.
@en
type
label
Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos
@nl
Efficacy of entecavir with or ...... ents with chronic hepatitis B.
@en
prefLabel
Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos
@nl
Efficacy of entecavir with or ...... ents with chronic hepatitis B.
@en
P2093
P1433
P1476
Efficacy of entecavir with or ...... ients with chronic hepatitis B
@en
P2093
Adrian Gadano
Anna S Lok
Cyril Llamoso
David Cohen
François Habersetzer
Giampiero Carosi
Meghan Lovegren
Ulus S Akarca
William Sievert
P304
619-628.e1
P356
10.1053/J.GASTRO.2012.05.037
P407
P50
P577
2012-05-27T00:00:00Z